<i>May the alterable use of the FIGO 1988 Staging System and the FIGO 2009 Staging System 	
for endometrial cancer lead to significant clinical mistakes?
</i>

Leszek Gottwald; Małgorzata Moszyńska-Zielińska; Grzegorz Surkont; Jerzy Korczyński; Wiesław Tyliński; Jarosław Szwalski; Michał Spych

eISSN: 2299-0038
ISSN: 1643-8876

Menopause Review/Przegląd Menopauzalny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

5/2011
vol. 10

Send email

Copy url:

abstract:

Original paper

May the alterable use of the FIGO 1988 Staging System and the FIGO 2009 Staging System for endometrial cancer lead to significant clinical mistakes?

Leszek Gottwald

,

Małgorzata Moszyńska-Zielińska

,

Grzegorz Surkont

,

Jerzy Korczyński

,

Wiesław Tyliński

,

Jarosław Szwalski

,

Michał Spych

Przegląd Menopauzalny 2011; 5: 372–377

Online publish date: 2011/11/05

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Gottwald L, Moszyńska-Zielińska M, Surkont G, et al. May the alterable use of the FIGO 1988 Staging System and the FIGO 2009 Staging System 	
for endometrial cancer lead to significant clinical mistakes?
. Menopause Review/Przegląd Menopauzalny. 2011;10(5):372-377.

APA

Gottwald, L., Moszyńska-Zielińska, M., Surkont, G., Korczyński, J., Tyliński, W.,  & Szwalski, J. et al. (2011). May the alterable use of the FIGO 1988 Staging System and the FIGO 2009 Staging System 	
for endometrial cancer lead to significant clinical mistakes?
. Menopause Review/Przegląd Menopauzalny, 10(5), 372-377.

Chicago

Gottwald, Leszek, Małgorzata Moszyńska-Zielińska, Grzegorz Surkont, Jerzy Korczyński, Wiesław Tyliński, Jarosław Szwalski,  and Michał Spych. 2011. "May the alterable use of the FIGO 1988 Staging System and the FIGO 2009 Staging System 	
for endometrial cancer lead to significant clinical mistakes?
". Menopause Review/Przegląd Menopauzalny 10 (5): 372-377.

Harvard

Gottwald, L., Moszyńska-Zielińska, M., Surkont, G., Korczyński, J., Tyliński, W., Szwalski, J.,  and Spych, M. (2011). May the alterable use of the FIGO 1988 Staging System and the FIGO 2009 Staging System 	
for endometrial cancer lead to significant clinical mistakes?
. Menopause Review/Przegląd Menopauzalny, 10(5), pp.372-377.

MLA

Gottwald, Leszek et al. "May the alterable use of the FIGO 1988 Staging System and the FIGO 2009 Staging System 	
for endometrial cancer lead to significant clinical mistakes?
." Menopause Review/Przegląd Menopauzalny, vol. 10, no. 5, 2011, pp. 372-377.

Vancouver

Gottwald L, Moszyńska-Zielińska M, Surkont G, Korczyński J, Tyliński W, Szwalski J et al. May the alterable use of the FIGO 1988 Staging System and the FIGO 2009 Staging System 	
for endometrial cancer lead to significant clinical mistakes?
. Menopause Review/Przegląd Menopauzalny. 2011;10(5):372-377.

Introduction: Since 2009 the new FIGO Staging System of endometrial cancer, which changed the previous FIGO 1988 Staging System, has been present. Unfortunately, parallel use of both classifications is observed.

Aim of study: to assess whether parallel use of the 2009 and the 1988 FIGO staging systems can cause significant therapeutic mistakes in patients with endometrioid endometrial cancer.

Material and methods: We analysed 262 patients with endometrioid endometrial cancer. The endometrial cancers were staged in both classifications. We analysed possible therapeutic mistakes caused by diverse nomenclature.

Results: The patients at low risk, intermediate risk, and high risk for relapse were presented in: 110 (41.6%), 109 (42.0%) and 43 (16.4%) cases, respectively. The possibility of inappropriate qualification for adjuvant treatment occurred in 102 patients (38.9%) if they were staged in the FIGO 1988 classification and interpreted as the FIGO 2009 classification, and similarly, in 65 patients (24.8%) if they were staged in the FIGO 2009 classification and interpreted as the FIGO 1988 classification. The risk of a decision mistake in terms of the adjuvant treatment due to diverse nomenclature was observed commonly in 167 patients (63.7%).

Conclusions: The common use of both FIGO staging systems for endometrioid endometrial cancer can cause significant therapeutic mistakes in terms of the adjuvant treatment. There is a need to use only the new FIGO 2009 Staging System for endometrial cancer and stop using the FIGO 1988 Staging System to avoid therapeutic mistakes.

keywords:

May the alterable use of the FIGO 1988 Staging System and the FIGO 2009 Staging System for endometrial cancer lead to significant clinical mistakes?

Leszek Gottwald , Małgorzata Moszyńska-Zielińska , Grzegorz Surkont , Jerzy Korczyński , Wiesław Tyliński , Jarosław Szwalski , Michał Spych

endometrial adenocarcinoma, endometrioid, staging, FIGO 1988 Staging System, FIGO 2009 Staging System

Leszek Gottwald

,

Małgorzata Moszyńska-Zielińska

,

Grzegorz Surkont

,

Jerzy Korczyński

,

Wiesław Tyliński

,

Jarosław Szwalski

,

Michał Spych